INSM vs. IQV: Insmed vs. IQVIA Stock Comparison

Company Profile

Insmed (INSM) and IQVIA (IQV) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INSM is classified in Biotechnology while IQV is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Insmed (INSM) reports a negative ROE of -72.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile IQVIA (IQV) reports 21.39%, ranking against industry peers normally.

Insmed (INSM) reports a negative net margin of -39.85%, usually indicating a net loss over the period. Meanwhile IQVIA (IQV) reports 8.05%, ranking against industry peers normally.

Insmed (INSM) reports a negative operating margin of -15.60%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile IQVIA (IQV) reports 13.73%, ranking against industry peers normally.

Profitability Metrics

Growth

Insmed (INSM) at 66.73% sits in the top revenue growth quartile, while IQVIA (IQV) at 5.87% is closer to the peer norm — faster top-line expansion for INSM.

Only one side can be read here: IQVIA (IQV) reports EPS growth of 4.67%, ranked against its industry; Insmed (INSM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Insmed (INSM) at 2.86 keeps current ratio within its industry’s typical mid-range, while IQVIA (IQV) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for IQV.

Both balance sheets lean debt-heavy versus peers, but IQV is more stretched: Insmed (INSM) at 1.01 sits in the higher-leverage quartile and IQVIA (IQV) at 2.40 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Neither Insmed (INSM) nor IQVIA (IQV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Insmed (INSM) nor IQVIA (IQV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: IQVIA (IQV) trades at 33.07 times trailing earnings, ranked against its peers, while Insmed (INSM) has no P/E ratio this period.

IQVIA (IQV) at 2.59 sits in the cheaper P/S ratio quartile while Insmed (INSM) at 16.52 prices around its industry’s middle — IQV costs less per dollar of sales, though read it alongside growth and margins.

Both look rich against book: IQVIA (IQV) at 6.73 sits in the upper P/B ratio quartile, and Insmed (INSM) at 34.55 prices even higher, above its industry range.

Valuation Metrics